Drug intelligence / Profile preview

luveltamab tazevibulin

Development stage: Phase 2
Lead developer: Sutro Biopharma
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Luveltamab tazevibulin is a novel homogeneous folate receptor alpha (FolRα) targeting antibody-drug conjugate (ADC). It uses a stable cleavable linker and a 3-aminophenyl hemiasterlin warhead to induce cytotoxic and immunologic cell death. Developed by Sutro Biopharma, it is primarily investigated for the treatment of ovarian cancer, particularly in patients with platinum-resistant disease. It has also been granted an orphan designation for the treatment of pediatric acute myeloid leukemia.

Brand names: luvelta
Other names: luveltamab tazevibulinSTRO-002STRO002STRO 002

Targets

FOLR1 (FRα)

Beyond the preview

Go deeper on luveltamab tazevibulin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on luveltamab tazevibulin.

Explore the full profile